Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine versus placebo and fluoxetine in children with major depressive disorder
2008-005353-38Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Lundbeck. Primary endpoint: Change in CDRS-R total score after treatment. Started Nov 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-005353-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005353-38.